The long-term persistence of tumor necrosis factor inhibitors in patients with moderate to severe immune-mediated rheumatic diseases: A nation-wide, population-based real-world study.

Huang, Jing-Yang; Leong, Pui-Ying; Ker, Amy; Chen, Hsin-Hua; Wei, James Cheng-Chung

Huang, Jing-Yang; Leong, Pui-Ying; Ker, Amy; Chen, Hsin-Hua; Wei, James Cheng-Chung.

Afiliação

Huang JY; Center for Health Data Science, Chung Shan Medical University Hospital, Taichung, Taiwan.
Leong PY; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Ker A; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Chen HH; School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Wei JC; Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.

Int J Rheum Dis ; 25(11): 1295-1305, 2022 Nov.

Article em En | MEDLINE | ID: mdl-35975402

Assuntos

Antirreumáticos; Doenças Reumáticas; Humanos; Feminino; Etanercepte/uso terapêutico; Adalimumab/uso terapêutico; Inibidores do Fator de Necrose Tumoral; Estudos Retrospectivos; Fator de Necrose Tumoral alfa; Antirreumáticos/uso terapêutico; Doenças Reumáticas/tratamento farmacológico; Infliximab/uso terapêutico

Palavras-chave

TNF-α inhibitor; drug persistence; immune-mediated rheumatic diseases

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Reumáticas / Antirreumáticos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Int J Rheum Dis Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google